1. SARS-CoV-2 infection documented by PCR or other nucleic acid test (NAT) within 3 days prior to randomization OR documented by NAT more than 3 days prior to randomization AND progressive disease suggestive of ongoing SARS-CoV-2 infection 2. Symptomatic COVID-19 disease 3. Duration of symptoms attributable to COVID-19 ≤ 12 days 4. Requiring inpatient hospital medical care for clinical manifestations of COVID-19 (admission for public health or quarantine only is not included) 5. Age ≥ 18 years 6. Willingness to abstain from participation in other COVID-19 treatment trials until after study Day 7 7. Provision of informed consent by participant or legally authorized representative

1. SARS-CoV-2 infection documented by PCR or other nucleic acid test (NAT) within 3 days prior to randomization OR documented by NAT more than 3 days prior to randomization AND progressive disease suggestive of ongoing SARS-CoV-2 infection 2. Symptomatic COVID-19 disease 3. Duration of symptoms attributable to COVID-19 ≤ 12 days 4. Requiring inpatient hospital medical care for clinical manifestations of COVID-19 (admission for public health or quarantine only is not included) 5. Age ≥ 18 years 6. Willingness to abstain from participation in other COVID-19 treatment trials until after study Day 7 7. Provision of informed consent by participant or legally authorized representative